monobenzone (benoquin) Report issue

Small molecule Approved FDA Priority Review FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Monobenzone is a topical drug used for medical depigmentation. The mechanism of action of monobenzone is not fully understood. Monobenzone is oxidized by tyrosinase from melanocytes to a toxic quinones which induce non-apoptotic melanocyte cell death.   NCATS

Chemistry

  • SMILES: OC1=CC=C(OCC2=CC=CC=C2)C=C1
  • InChIKey: VYQNWZOUAUKGHI-UHFFFAOYSA-N
  • Mol. Mass: 200.2332
  • ALogP: 2.97
  • ChEMBL Molecule:
    monobenzone  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Topical
  • Pro Drug: No

Alternative names

4-(benzyloxyl)phenol | 4-benzyloxyphenol | 4-(benzyloxy)phenol | 4-benzyloxy-phenol | 4-(phenylmethoxy)phenol | agerite alba | benoquin | benzoquin | benzylhydroquinone | benzyl p-hydroxyphenyl ether | hydrochinon monobenzylether | hydroquinone benzyl ether | hydroquinone monobenzyl ether | icn brand of monobenzone | leucodinine | monobenzon | monobenzona | monobenzone | monobenzonum | monobenzyl ether hydroquinone | monobenzyl ether of hydroquinone | monobenzyl hydroquinone | novo-depigman | p-benzyloxyphenol | p-(benzyloxy)phenol | p-hydroxyphenyl benzyl ether

Organizations (1)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (1)


 

Hypopigmentation (approved 1952)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Melanoma ()

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue